DOCSLIB.ORG

Sleeping Sickness) the Road to Elimination Revisited—Achievements and Remaining Challenges

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sleeping Sickness) the Road to Elimination Revisited—Achievements and Remaining Challenges Human African Trypanosomiasis African Human • Ch ristian Burri Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited—Achievements and Remaining Challenges Edited by Christian Burri Printed Edition of the Special Issue Published in Tropical Medicine and Infectious Disease www.mdpi.com/journal/tropicalmed Human African Trypanosomiasis (Sleeping Sickness) Human African Trypanosomiasis (Sleeping Sickness) The Road to Elimination Revisited—Achievements and Remaining Challenges Special Issue Editor Christian Burri MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin Special Issue Editor Christian Burri Swiss Tropical & Public Health Institute Switzerland Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Tropical Medicine and Infectious Disease (ISSN 2414-6366) (available at: https://www.mdpi.com/ journal/tropicalmed/special issues/HAT). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03928-963-9 (Pbk) ISBN 978-3-03928-964-6 (PDF) Cover image courtesy of Swiss Tropical & Public Health Institute. Trypanosoma brucei; F. Brand, Swiss TPH; Picture taken with the transmission electron microscope at the Center for Cellular Imaging and NanoAnalytics, University of Basel, Switzerland c 2020 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editor ...................................... vii Preface to ”Human African Trypanosomiasis (HAT, Sleeping Sickness)” ............. ix Christian Burri Sleeping Sickness at the Crossroads Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 57, doi:10.3390/tropicalmed5020057 ........ 1 Emma Michelle Taylor and James Smith Product Development Partnerships: Delivering Innovation for the Elimination of African Trypanosomiasis? Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 11, doi:10.3390/tropicalmed5010011 ........ 13 Philippe Neau, Heinz H¨anel, Val´erie Lameyre, Nathalie Strub-Wourgaft and Luc Kuykens Innovative Partnerships for the Elimination of Human African Trypanosomiasis and the Development of Fexinidazole Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 17, doi:10.3390/tropicalmed5010017 ........ 31 Florent Mbo, Wilfried Mutombo, Digas Ngolo, Patrice Kabangu, Olaf Valverde Mordt, Nathalie Strub Wourgaft and Erick Mwamba How Clinical Research Can Contribute to Strengthening Health Systems in Low Resource Countries Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 48, doi:10.3390/tropicalmed5020048 ........ 45 Shona J Lee, Renah J Apio and Jennifer J Palmer Centering Patient Expectations of a Novel Home-Based Oral Drug Treatment among T. b. rhodesiense Human African Trypanosomiasis Patients in Uganda Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 16, doi:10.3390/tropicalmed5010016 ........ 55 Jean-Benoˆıt Falisse, Erick Mwamba-Miaka and Alain Mpanya Whose Elimination? Frontline Workers’ Perspectives on the Elimination of the Human African Trypanosomiasis and Its Anticipated Consequences Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 6, doi:10.3390/tropicalmed5010005 ......... 69 Jennifer J. Palmer, Caroline Jones, Elizeous I Surur and Ann H Kelly Understanding the Role of the Diagnostic ‘Reflex’ in the Elimination of Human African Trypanosomiasis Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 52, doi:10.3390/tropicalmed5020052 ........ 85 Matthieu Nkieri, Florent Mbo, Papy Kavunga, Pathou Nganzobo, Titus Mafolo, Chalet Selego and Eric Mwamba Miaka An Active Follow-up Strategy for Serological Suspects of Human African Trypanosomiasis with Negative Parasitology Set up by a Health Zone Team in the Democratic Republic of Congo Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 53, doi:10.3390/tropicalmed5020053 ........103 Enock Matovu, Claire Mack Mugasa, Peter Waiswa, Annah Kitibwa, Alex Boobo and Joseph Mathu Ndung’u Haemoparasitic Infections in Cattle from a Trypanosoma brucei Rhodesiense Sleeping Sickness Endemic District of Eastern Uganda Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 24, doi:10.3390/tropicalmed5010024 ........113 v Junior Mudji, Jonathan Benhamou, Erick Mwamba-Miaka, Christian Burri and Johannes Blum The Flipside of Eradicating a Disease; Human African Trypanosomiasis in a Woman in Rural Democratic Republic of Congo: A Case Report Reprinted from: Trop. Med. Infect. Dis. 2019, 4, 142, doi:10.3390/tropicalmed4040142 .......123 Junior Mudji, Anna Blum, Leticia Grize, Rahel Wampfler, Marie-Th´er`ese Ruf, Lieselotte Cnops, Beatrice Nickel, Christian Burri and Johannes Blum Gambiense Human African Trypanosomiasis Sequelae after Treatment: A Follow-Up Study 12 Years after Treatment Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 10, doi:10.3390/tropicalmed5010010 ........129 Jorge Seixas, Jorge Atouguia, Teofilo ´ Josenando, Gede˜ao Vatunga, Constantin Miaka Mia Bilenge, Pascal Lutumba and Christian Burri Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 5, doi:10.3390/tropicalmed5010005 .........145 Ulrich-Dietmar Madeja and Ulrike Schroeder From Colonial Research Spirit to Global Commitment: Bayer and African Sleeping Sickness in the Mirror of History Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 42, doi:10.3390/tropicalmed5010042 ........161 Harry P. De Koning The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 14, doi:10.3390/tropicalmed5010014 ........169 Emily A. Dickie, Federica Giordani, Matthew K. Gould, Pascal M¨aser, Christian Burri, Jeremy C. Mottram, Srinivasa P. S. Rao and Michael P. Barrett New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 29, doi:10.3390/tropicalmed5010029 ........193 Srinivasa P S Rao, Suresh B Lakshminarayana, Jan Jiricek, Marcel Kaiser, Ryan Ritchie, Elmarie Myburgh, Frantisek Supek, Tove Tuntland, Advait Nagle, Valentina Molteni, Pascal M¨aser, Jeremy C Mottram, Michael P Barrett and Thierry T Diagana Anti-Trypanosomal Proteasome Inhibitors Cure Hemolymphatic and Meningoencephalic Murine Infection Models of African Trypanosomiasis Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 28, doi:10.3390/tropicalmed5010028 ........209 Frederick S. Buckner, Andriy Buchynskyy, Pendem Nagendar, Donald A. Patrick, J. Robert Gillespie, Zackary Herbst, Richard R. Tidwell and Michael H. Gelb Phenotypic Drug Discovery for Human African Trypanosomiasis: A Powerful Approach Reprinted from: Trop. Med. Infect. Dis. 2020, 5, 23, doi:10.3390/tropicalmed5010023 ........223 Christopher K. Kariuki, Benoit Stijlemans and Stefan Magez The Trypanosomal Transferrin Receptor of Trypanosoma Brucei—A Review Reprinted from: Trop. Med. Infect. Dis. 2019, 4, 126, doi:10.3390/tropicalmed4040126 .......241 Kah Tee Lim, Chiann Ying Yeoh, Zafarina Zainuddin and Mohd. Ilham Adenan (+)-Spectaline and Iso-6-Spectaline Induce a Possible Cross-Talk between Autophagy and Apoptosis in Trypanosoma brucei rhodesiense Reprinted from: Trop. Med. Infect. Dis. 2019, 4, 98, doi:10.3390/tropicalmed4030098 ........259 vi About the Special Issue Editor Christian Burri PhD, is the Deputy Head of the Department of Medicine and the Head of the Medicines Implementation Research Unit at the Swiss TPH, and Professor of Pharmacy & Clinical Pharmacology at the Department of Pharmaceutical Sciences, University of Basel. For almost 25 years, he has been involved in the management and conduct of clinical trials on drugs and vaccines against neglected tropical and poverty-related diseases, mainly in low income countries. In 2018, he handed over this service-oriented responsibility and founded a research group studying the implementation of medicines in resource-low settings in the two main fields of interests of access and pharmacoepidemiology. Throughout his training and professional career, he has had the privilege of becoming involved in most aspects of drug research and development, including gene cloning and parasite cultivation, drug screening, pharmacology and toxicology, lead selection, the conducting of clinical trials of Phases I–III, quality management, ethical and regulatory tasks, but also in various aspects of public health and the implementation of new interventions. Despite his involvement on a broad range of topics and contribution to various diseases, the original and continued passion of Prof. Burri is sleeping sickness (human African trypanosomiasis), where he has significantly contributed to improvement of the treatment. Prof. Burri has been trained as a pharmacist at the University of Bern, Switzerland, holds a PhD in medical parasitology from the University of Basel, and conducted postdoctoral training in molecular pharmacology at the Johns Hopkins University, Baltimore. He has held a Diploma in Pharmaceutical Medicine of the
Load more

Recommended publications
  • The Bill & Melinda Gates Foundation Tax Return Was E-Filed with The
    The Bill & Melinda Gates Foundation tax return was e-filed with the Internal Revenue Service. The tax return and accompanying attachments posted on our website are presented as a view of the electronically filed data. Please note for ease of navigating the tax return we have bookmarked the various sections of the return. efile GRAPHIC print - DO NOT PROCESS ORIGINAL DATA - EIN: 562618866 Return of Private Foundation OMB No. 1545-0052 Form 990-PF or Section 4947(a)(1) Nonexempt Charitable Trust Treated as a Private Foundation 2007 Department of the Treasury Note: The foundation may be able to use a copy of this return to satisfy state reporting requirements. Internal Revenue Service For calendar year 2007 , or tax year beginning 01-01-2007 and ending 12-31-2007 G Check all that apply: Initial return Final return Amended return Address change Name change Name of foundation A Employer identification number Use the IRS BILL & MELINDA GATES FOUNDATION label. 56-2618866 Otherwise, B Telephone number (see page 10 of the instructions) print Number and street (or P.O. box number if mail is not delivered to street address) Room/ suite or type. 1551 EASTLAKE AVENUE EAST (206) 709-3100 See Specific Instructions. City or town, state, and ZIP code C If exemption application is pending, check here SEATTLE, WA 98102 D 1. Foreign organizations, check here . H Check type of organization: Section 501(c)(3) exempt private foundation 2. Foreign organizations meeting the 85% test, check here and attach computation Section 4947(a)(1) nonexempt charitable trust Other taxable private foundation E If private foundation status was terminated I Fair market value of all assets at end J Accounting method: Cash Accrual under section 507(b)(1)(A), check here of year (from Part II, col.
    [Show full text]
  • Developing Vaccines for Neglected Diseases
    Developing Vaccines for Neglected Diseases Vaccine Technologies II Albufeira, Portugal June 5th, 2008 Douglas Holtzman, Ph.D., M.P.H. Senior Program Officer, Global Health Program Bill & Melinda Gates Foundation 1 Three Programs, One Goal: Equity US Program » High school education » Public library internet access Global Development » Financial services for the poor (e.g. microfinance) » Agricultural productivity and markets Global Health 2 Perspective on Global Health The vision: To ensure that a child born in the developing world has the same chance for good health as a child born in the developed world The goal: Build on advances in science and technology to save lives, improve health, and reduce disease in the developing world 3 Prioritization Burden of disease Inequity of burden Lack of attention Possibility for impact 4 Disease Areas HIV (vaccines, microbicides, treatment, prevention, education) TB (drugs, vaccines, diagnostics) Malaria (drugs, vaccines, vector control, diagnostics, scale-up) Pneumonia Diarrhea Nutrition Maternal Health Discover, develop and deliver Kinetoplastids innovative solutions Helminths HPV Dengue/Japanese Encephalitis Polio 5 Partnerships Global Alliance for Vaccines and Immunization (GAVI) Global Fund for AIDS, TB and Malaria HIV Vaccine Enterprise Medicines for Malaria Venture (MMV) Malaria Vaccine Initiative (MVI) MACEPA PATH Vaccine Solutions (PVS) Aeras (TB Vaccines) Global Alliance for TB Drug Development (GATB) ACHAP Grand Challenges in Global Health IVI/PDVI Etc….
    [Show full text]
  • Metformin Selectively Targets Redox Control of Complex I Energy Transduction
    Heriot-Watt University Research Gateway Metformin selectively targets redox control of complex I energy transduction Citation for published version: Cameron, AR, Logie, L, Patel, K, Erhardt, S, Bacon, S, Middleton, P, Harthill, J, Forteath, C, Coats, JT, Kerr, C, Curry, H, Stewart, D, Sakamoto, K, Repišák, P, Paterson, MJ, Hassinen, I, McDougall, GJ & Rena, G 2018, 'Metformin selectively targets redox control of complex I energy transduction', Redox Biology, vol. 14, pp. 187-197. https://doi.org/10.1016/j.redox.2017.08.018 Digital Object Identifier (DOI): 10.1016/j.redox.2017.08.018 Link: Link to publication record in Heriot-Watt Research Portal Document Version: Publisher's PDF, also known as Version of record Published In: Redox Biology General rights Copyright for the publications made accessible via Heriot-Watt Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy Heriot-Watt University has made every reasonable effort to ensure that the content in Heriot-Watt Research Portal complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 24. Sep. 2021 Redox Biology 14 (2018) 187–197 Contents lists available at ScienceDirect Redox Biology journal homepage: www.elsevier.com/locate/redox Research paper Metformin selectively targets redox control of complex I energy transduction MARK Amy R.
    [Show full text]
  • E-Newsletter
    October 2009 Center for Clinical and Translational Science e-Newsletter Center News New Certificate Program in Clinical and Translational Science Graduates First Class By Angela Slattery In September 2008, a new Certificate Program in Clinical and Translational Science began at Rockefeller University. Eighteen students from across campus participated in the inaugural class. In June 2009, all of the program’s students graduated and received a Certificate in Clinical and Translational Science from the university. The Certificate Program, which is sponsored by the Center for 2009 Inaugural Certificate in Clinical and Translational Science Class Clinical and Translational Science or his own hypothetical human subjects The protocols that were submitted (CCTS), was developed in collaboration protocol, including an informed consent in fulfillment of the requirement of with students and postdoctoral fellows form. To further familiarize the students the course were of exceptionally high to provide trainees with an introduction with the protocol review process, the caliber and offered insights into the to the principles and practices of clinical students then functioned as a mock IRB, clinical research interests of the talented and translational research. reviewing each of the protocols and group of investigators who enrolled in The Certificate Program is a one year offering suggestions to insure the optimal the program. Dr. Barry Coller, director program that consists of two courses. design and the greatest protection of the of the Certificate Program stated, Each student was required to create her human subjects that would participate. (continued on page 2) CCTS and Clinical Directors Network Successfully Complete First Collaborative Project By Angela Slattery In the fall of 2008, through the history phenotyping system.
    [Show full text]
  • “Salivary Gland Cellular Architecture in the Asian Malaria Vector Mosquito Anopheles Stephensi”
    Wells and Andrew Parasites & Vectors (2015) 8:617 DOI 10.1186/s13071-015-1229-z RESEARCH Open Access “Salivary gland cellular architecture in the Asian malaria vector mosquito Anopheles stephensi” Michael B. Wells and Deborah J. Andrew* Abstract Background: Anopheles mosquitoes are vectors for malaria, a disease with continued grave outcomes for human health. Transmission of malaria from mosquitoes to humans occurs by parasite passage through the salivary glands (SGs). Previous studies of mosquito SG architecture have been limited in scope and detail. Methods: We developed a simple, optimized protocol for fluorescence staining using dyes and/or antibodies to interrogate cellular architecture in Anopheles stephensi adult SGs. We used common biological dyes, antibodies to well-conserved structural and organellar markers, and antibodies against Anopheles salivary proteins to visualize many individual SGs at high resolution by confocal microscopy. Results: These analyses confirmed morphological features previously described using electron microscopy and uncovered a high degree of individual variation in SG structure. Our studies provide evidence for two alternative models for the origin of the salivary duct, the structure facilitating parasite transport out of SGs. We compare SG cellular architecture in An. stephensi and Drosophila melanogaster, a fellow Dipteran whose adult SGs are nearly completely unstudied, and find many conserved features despite divergence in overall form and function. Anopheles salivary proteins previously observed at the basement membrane were localized either in SG cells, secretory cavities, or the SG lumen. Our studies also revealed a population of cells with characteristics consistent with regenerative cells, similar to muscle satellite cells or midgut regenerative cells. Conclusions: This work serves as a foundation for linking Anopheles stephensi SG cellular architecture to function and as a basis for generating and evaluating tools aimed at preventing malaria transmission at the level of mosquito SGs.
    [Show full text]
  • Health Information for International Travel 1996-97
    CDCCENTERS FOR DISEASE CONTROL AND PREVENTION Health Information for International Travel 1996-97 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service This document was created with FrameMaker 4.0.4 ATTENTION READERS It is impossible for an annual publication on international travel to remain absolutely current given the nature of disease transmission in the world today. For readers of this text to be the most up-to-date on travel-related diseases and recommendations, this text must be used in conjunction with the other services provided by the Travelers’ Health Section of the Centers for Disease Control and Prevention (CDC). Changes such as vaccine requirements, disease outbreaks, drug availability, or emerging infections will be posted promptly on these services. For these and other changes, please consult either our Voice or Fax Information Service at 404-332-4559 or our Internet address on the World Wide Web Server at http://www.cdc.gov or the File Transfer Protocol server at ftp.cdc.gov . Because certain countries require vaccination against yellow fever only if a traveler arrives from a country currently infected with this disease, it is essential that up-to-date information regarding infected areas be maintained for reference. The CDC publishes a biweekly "Summary of Health Information for Interna- tional Travel" (Blue Sheet) which lists yellow fever infected areas. Subscriptions to the Blue Sheet are available to health departments, physicians, travel agencies, international airlines, shipping companies, travel clinics, and other private and public agencies that advise international travelers concerning health risks they may encounter when visiting other countries.
    [Show full text]
  • Rediscovery of Fexinidazole
    New Drugs against Trypanosomatid Parasites: Rediscovery of Fexinidazole INAUGURALDISSERTATION zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Marcel Kaiser aus Obermumpf, Aargau Basel, 2014 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Dieses Werk ist unter dem Vertrag „Creative Commons Namensnennung-Keine kommerzielle Nutzung-Keine Bearbeitung 3.0 Schweiz“ (CC BY-NC-ND 3.0 CH) lizenziert. Die vollständige Lizenz kann unter creativecommons.org/licenses/by-nc-nd/3.0/ch/ eingesehen werden. 1 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel auf Antrag von Prof. Reto Brun, Prof. Simon Croft Basel, den 10. Dezember 2013 Prof. Dr. Jörg Schibler, Dekan 2 3 Table of Contents Acknowledgement .............................................................................................. 5 Summary ............................................................................................................ 6 Zusammenfassung .............................................................................................. 8 CHAPTER 1: General introduction ................................................................. 10 CHAPTER 2: Fexinidazole - A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness ........ 26 CHAPTER 3: Anti-trypanosomal activity of Fexinidazole – A New Oral Nitroimidazole Drug Candidate for the Treatment
    [Show full text]
  • Autophagy in Trypanosomatids
    Cells 2012, 1, 346-371; doi:10.3390/cells1030346 OPEN ACCESS cells ISSN 2073-4409 www.mdpi.com/journal/cells Review Autophagy in Trypanosomatids Ana Brennand 1,†, Eva Rico 2,†,‡ and Paul A. M. Michels 1,* 1 Research Unit for Tropical Diseases, de Duve Institute, Université catholique de Louvain, Avenue Hippocrate 74, postal box B1.74.01, B-1200 Brussels, Belgium; E-Mail: [email protected] 2 Department of Biochemistry and Molecular Biology, University Campus, University of Alcalá, Alcalá de Henares, Madrid, 28871, Spain; E-Mail: [email protected] † These authors contributed equally to this work. ‡ Present Address: Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, School of Biological Sciences, King’s Buildings, University of Edinburgh, West Mains Road, Edinburgh EH9 3JT, UK. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +32-2-7647473; Fax: +32-2-7626853. Received: 28 June 2012; in revised form: 14 July 2012 / Accepted: 16 July 2012 / Published: 27 July 2012 Abstract: Autophagy is a ubiquitous eukaryotic process that also occurs in trypanosomatid parasites, protist organisms belonging to the supergroup Excavata, distinct from the supergroup Opistokontha that includes mammals and fungi. Half of the known yeast and mammalian AuTophaGy (ATG) proteins were detected in trypanosomatids, although with low sequence conservation. Trypanosomatids such as Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are responsible for serious tropical diseases in humans. The parasites are transmitted by insects and, consequently, have a complicated life cycle during which they undergo dramatic morphological and metabolic transformations to adapt to the different environments.
    [Show full text]
  • Programme Against African Trypanosomiasis Year 2006 Volume
    ZFBS 1""5 1SPHSBNNF *44/ WPMVNF "HBJOTU "GSJDBO QBSU 5SZQBOPTPNJBTJT 43%43%!.$4290!./3/-)!3)3).&/2-!4)/. $EPARTMENTFOR )NTERNATIONAL $EVELOPMENT year 2006 PAAT Programme volume 29 Against African part 1 Trypanosomiasis TSETSE AND TRYPANOSOMIASIS INFORMATION Numbers 13466–13600 Edited by James Dargie Bisamberg Austria FOOD AND AGRICULTURE ORGANIZATION OF THE UNITED NATIONS Rome, 2006 The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. All rights reserved. Reproduction and dissemination of material in this in- formation product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to the Chief, Electronic Publishing Policy and Support Branch, Information Division, FAO, Viale delle Terme di Caracalla, 00100 Rome, Italy or by e-mail to [email protected] © FAO 2006 Tsetse and Trypanosomiasis Information Volume 29 Part 1, 2006 Numbers 13466–13600 Tsetse and Trypanosomiasis Information TSETSE AND TRYPANOSOMIASIS INFORMATION The Tsetse and Trypanosomiasis Information periodical has been established to disseminate current information on all aspects of tsetse and trypanosomiasis research and control to institutions and individuals involved in the problems of African trypanosomiasis.
    [Show full text]
  • Human African Trypanosomiasis in Non-Endemic Countries (2000-2010)
    1 REVIEW Human African Trypanosomiasis in Non-Endemic Countries (2000–2010) Pere P. Simarro, PhD,∗ Jose´ R. Franco, MD,∗ Giuliano Cecchi, MD,† Massimo Paone, MD,† Abdoulaye Diarra, PhD,‡ Jose´ A. Ruiz Postigo, PhD,§ and Jean G. Jannin, PhD∗ ∗World Health Organization, Control of Neglected Tropical Diseases, Innovativ and Intensified Disease Management, Geneva, Switzerland; †Food and Agriculture Organization of the United Nations (FAO), Animal Production and Health Division, Rome, Italy; ‡World Health Organization, Regional Office for Africa, Brazzaville, Congo; §World Health Organization, Regional Office for the Eastern Mediterranean, Cairo, Egypt DOI: 10.1111/j.1708-8305.2011.00576.x Background. Human African trypanosomiasis (HAT) can affect travelers to sub-Saharan Africa, as well as migrants from disease endemic countries (DECs), posing diagnosis challenges to travel health services in non-disease endemic countries (non-DECs). Methods. Cases reported in journals have been collected through a bibliographic research and complemented by cases reported to the World Health Organization (WHO) during the process to obtain anti-trypanosome drugs. These drugs are distributed to DECs solely by WHO. Drugs are also provided to non-DECs when an HAT case is diagnosed. However, in non-DEC pentamidine can also be purchased in the market due to its indication to treat Pneumocystis and Leishmania infections. Any request for drugs from non-DECs should be accompanied by epidemiological and clinical data on the patient. Results. During the period 2000 to 2010, 94 cases of HAT were reported in 19 non-DECs. Seventy-two percent of them corresponded to the Rhodesiense form, whereas 28% corresponded to the Gambiense. Cases of Rhodesiense HAT were mainly diagnosed in tourists after short visits to DECs, usually within a few days of return.
    [Show full text]
  • 2019 Annual Report
    Alfred P. Sloan Foundation $ 2019 Annual Report 2019 Annual Report 1 Alfred P. Sloan Foundation $ 2019 Annual Report Driven by the promise of great ideas. Alfred P. Sloan Foundation $ 2019 Annual Report Contents Preface 2 Mission 3 From the President 4 On Racism and Our Responsibilities 6 The Year in Discovery 8 Deep Carbon Observatory 18 Microbiology of the Built Environment 21 About the Grants Listing 24 2019 Grants by Program 25 2019 Financial Review 123 Audited Financial Statements and Schedules 125 Board of Trustees 156 Officers and Staff 157 Index of 2019 Grant Recipients 158 Cover: A student participant in the Environmentor program holds a turtle. An initiative of RISE (the Rockaway Institute for Sustainability), the Environmentor program is a Sloan-supported science research mentorship that offers NYC high school students the opportunity to conduct authentic, hands-on environmental research on Jamaica Bay and the Rockaway shoreline. (PHOTO: RISE ROCKAWAY) 1 Alfred P. Sloan Foundation $ 2019 Annual Report Preface The Alfred P. Sloan Foundation administers a private fund for the benefit of the public. It accordingly recognizes the responsibility of making periodic reports to the public on the management of this fund. The Foundation therefore submits this public report for the year 2019. 2 Alfred P. Sloan Foundation $ 2019 Annual Report Mission The Alfred P. Sloan Foundation makes grants primarily to support original research and education related to science, technology, engineering, mathematics, and economics. The Foundation believes that these fields— and the scholars and practitioners who work in them— are chief drivers of the nation’s health and prosperity.
    [Show full text]
  • Avaliação Do Potencial Carcinogênico Do Megazol, Agente Anti-Chagásico, E Obtenção De Nanopartículas De Poli(Ε- Caprolactona) Contendo Megazol
    MARTA LOPES LIMA Avaliação do potencial carcinogênico do Megazol, agente anti-chagásico, e obtenção de nanopartículas de poli(ε- caprolactona) contendo Megazol Dissertação apresentada ao Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/IPT, para obtenção do Título de Mestre em Biotecnologia. São Paulo 2011 1 MARTA LOPES LIMA Avaliação do potencial carcinogênico do Megazol, agente anti-chagásico, e obtenção de nanopartículas de poli(ε- caprolactona) contendo Megazol Dissertação para o exame de qualificação apresentada ao Programa de Pós-Graduação Interunidades em Biotecnologia USP/Instituto Butantan/ IPT, para obtenção do Título de Mestre em Biotecnologia. Área de Concentração: Biotecnologia Orientadora: Drª. Cristina Northfleet de Albuquerque Versão original São Paulo 2011 2 3 4 A mulher que em nenhum momento mediu esforços para a realização dos meus sonhos, ao meu exemplo de caráter, dedicação e fé Obrigada Mãe!!! 5 Agradecimentos Ao Laboratório de Química, Bioquímica e Biologia Molecular de Alimentos da Faculdade de Ciências Farmacêuticas, em especial para a Pós-Doutora Claudinéia Aparecida Soares, sem seu auxílio esta pesquisa não teria sido finalizada. Obrigada, pelas horas perdidas de discussões e trabalho árduo, especialmente finais de semana. A Pós-Doutora Nádia Araci Bou-Chacra e graduanda Juliana Conte pelo auxílio no preparo das nanopartículas. Ao Laboratório de Planejamento e Síntese de Quimioterápicos Potencialmente Ativos em Doenças Negligenciadas da Faculdade de Ciências Farmacêuticas, pelo uso dos equipamentos. Ao laboratório de Farmacotécnica da Faculdade de Ciências Farmacêuticas, em especial a Drª Vladi Olga Consiglieri e Dr. Guilherme Tavares pelo auxílio no desenvolvimento do método analítico aqui empregado. A toda família Zucchi pelo apoio, incentivo e hospitalidade.
    [Show full text]